ID

43523

Descripción

Breath Test for Women Receiving Tamoxifen in the Prevention or Treatment of Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00873366

Link

https://clinicaltrials.gov/show/NCT00873366

Palabras clave

Versiones (2)
  1. 23/10/17 23/10/17 -
  2. 20/9/21 20/9/21 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

20 de septiembre de 2021

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Breast Cancer NCT00873366

Inglés

Eligibility Breast Cancer NCT00873366

1 formularios  
Criteria
Descripción

Criteria

eligible to receive tamoxifen for 6 months for either the prevention or treatment of non-invasive or invasive, stage i-iii breast cancer
Descripción

Tamoxifen | Prophylactic treatment Breast Carcinoma TNM Breast tumor staging | Prophylactic treatment Invasive carcinoma of breast TNM Breast tumor staging | Therapeutic procedure Breast Carcinoma TNM Breast tumor staging | Therapeutic procedure Invasive carcinoma of breast TNM Breast tumor staging

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0039286
UMLS CUI [2,1]
C0199176
UMLS CUI [2,2]
C0678222
UMLS CUI [2,3]
C0474926
UMLS CUI [3,1]
C0199176
UMLS CUI [3,2]
C0853879
UMLS CUI [3,3]
C0474926
UMLS CUI [4,1]
C0087111
UMLS CUI [4,2]
C0678222
UMLS CUI [4,3]
C0474926
UMLS CUI [5,1]
C0087111
UMLS CUI [5,2]
C0853879
UMLS CUI [5,3]
C0474926
cyp2d6 genotype known
Descripción

CYP2D6 gene Known

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1332830
UMLS CUI [1,2]
C0205309
patients determined to be cyp2d6 poor metabolizers (by determination of a genotype test by their mayo physician prior to study registration) are eligible to proceed with the initial breath test only
Descripción

CYP2D6 gene Poor metabolizer | cytochrome p450 2D6 genotype | Breath Test

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1332830
UMLS CUI [1,2]
C3845231
UMLS CUI [2]
C2164095
UMLS CUI [3]
C0006153
hormone receptor status not specified
Descripción

Hormone Receptor Status Unspecified

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0019929
UMLS CUI [1,2]
C0449438
UMLS CUI [1,3]
C0205370
patient characteristics:
Descripción

Client Characteristics

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0815172
menopausal status not specified
Descripción

Menopausal Status Unspecified

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C3829127
UMLS CUI [1,2]
C0205370
ecog performance status 0-2
Descripción

ECOG performance status

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1520224
life expectancy > 6 months
Descripción

Life Expectancy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0023671
no known impaired hepatic activity defined as ≥ grade 3 ast, alkaline phosphatase, or total bilirubin
Descripción

Exclusion Liver Dysfunction Grade | Aspartate aminotransferase measurement | Alkaline phosphatase measurement | Serum total bilirubin measurement

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C2828389
UMLS CUI [1,2]
C0086565
UMLS CUI [1,3]
C0441800
UMLS CUI [2]
C0201899
UMLS CUI [3]
C0201850
UMLS CUI [4]
C1278039
no pulmonary disease (e.g., asthma or other respiratory disease) associated with hypercapnia
Descripción

Exclusion Criteria | Lung disease Associated with Hypercapnia | Asthma | Respiration Disorders

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0680251
UMLS CUI [2,1]
C0024115
UMLS CUI [2,2]
C0332281
UMLS CUI [2,3]
C0020440
UMLS CUI [3]
C0004096
UMLS CUI [4]
C0035204
no uncontrolled metabolic disease (e.g., diabetes in the presence of gastroparesis, uncontrolled congestive heart failure, or uncontrolled gastrointestinal disorders [e.g., gerd])
Descripción

Exclusion Criteria | Metabolic Diseases Uncontrolled | Gastroparesis due to diabetes mellitus | Congestive heart failure Uncontrolled | Gastrointestinal Diseases Uncontrolled | Gastroesophageal reflux disease

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0680251
UMLS CUI [2,1]
C0025517
UMLS CUI [2,2]
C0205318
UMLS CUI [3]
C0267176
UMLS CUI [4,1]
C0018802
UMLS CUI [4,2]
C0205318
UMLS CUI [5,1]
C0017178
UMLS CUI [5,2]
C0205318
UMLS CUI [6]
C0017168
no prior adverse reaction to dextromethorphan
Descripción

Exclusion Adverse reactions Dextromethorphan

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C2828389
UMLS CUI [1,2]
C0559546
UMLS CUI [1,3]
C0011816
no history of chronic liver disease (e.g., hepatitis b or hepatitis c, alcoholic liver disease, cirrhosis, or fibrotic disease)
Descripción

Exclusion Criteria | Chronic liver disease | Hepatitis B, Chronic | Hepatitis C, Chronic | Chronic alcoholic liver disease | Liver Cirrhosis chronic | Chronic fibrosis

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0680251
UMLS CUI [2]
C0341439
UMLS CUI [3]
C0524909
UMLS CUI [4]
C0524910
UMLS CUI [5]
C4076349
UMLS CUI [6,1]
C0023890
UMLS CUI [6,2]
C0205191
UMLS CUI [7]
C0334133
able and willing to fast overnight prior to the study session
Descripción

Fasting Overnight Able | Fasting Overnight Willing

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0015663
UMLS CUI [1,2]
C0439583
UMLS CUI [1,3]
C0085732
UMLS CUI [2,1]
C0015663
UMLS CUI [2,2]
C0439583
UMLS CUI [2,3]
C0600109
willing to return to mayo clinic for follow-up
Descripción

Follow-up Willing

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C3274571
UMLS CUI [1,2]
C0600109
willing to provide biologic specimens
Descripción

Biospecimen Provide Willing

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C2347026
UMLS CUI [1,2]
C1999230
UMLS CUI [1,3]
C0600109
prior concurrent therapy:
Descripción

Therapeutic procedure

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0087111
more than 24 hours since prior medications known to slow gastric emptying or gastrointestinal motility (e.g., alcohol, opioid analgesics, anticholinergics [e.g., antihistamines], and loperamide)
Descripción

Pharmaceutical Preparations Previous Slowing Gastric Emptying | Pharmaceutical Preparations Previous Slowing Gastrointestinal Motility | Alcohol | Analgesics, Opioid | Anticholinergic Agents | Antihistamines | Loperamide

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0205156
UMLS CUI [1,3]
C0439834
UMLS CUI [1,4]
C0017127
UMLS CUI [2,1]
C0013227
UMLS CUI [2,2]
C0205156
UMLS CUI [2,3]
C0439834
UMLS CUI [2,4]
C0017184
UMLS CUI [3]
C0001975
UMLS CUI [4]
C0002772
UMLS CUI [5]
C0242896
UMLS CUI [6]
C0019590
UMLS CUI [7]
C0023992
UMLS CUI [8]
C0162373
more than 4 weeks since prior and no concurrent cyp2d6 inhibitors or concurrent serotonin-reuptake inhibitors known to be potent cyp2d6 inhibitors (e.g.,paroxetine [paxil®] and fluoxetine [prozac®]
Descripción

CYP2D6 Inhibitors Previous | Selective Serotonin Reuptake Inhibitors Previous | Paroxetine | Paxil | Fluoxetine | Prozac

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C3850058
UMLS CUI [1,2]
C0205156
UMLS CUI [2,1]
C0360105
UMLS CUI [2,2]
C0205156
UMLS CUI [3]
C0070122
UMLS CUI [4]
C0376414
UMLS CUI [5]
C0016365
UMLS CUI [6]
C0162373
if mild to moderate inhibitors of cyp2d6 are medically necessary, patients may go back on after the 8-week time point
Descripción

CYP2D6 Inhibitors Mild Patient need for | CYP2D6 Inhibitors Moderate Patient need for

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C3850058
UMLS CUI [1,2]
C2945599
UMLS CUI [1,3]
C0686904
UMLS CUI [2,1]
C3850058
UMLS CUI [2,2]
C0205081
UMLS CUI [2,3]
C0686904
more than 4 weeks since prior and no concurrent monoamine-oxidase inhibitors (e.g., furazolidone, phenelzine, procarbazine, selegiline, and tranylcypromine)
Descripción

Monoamine Oxidase Inhibitors Previous | Furazolidone | Phenelzine | Procarbazine | Selegiline | Tranylcypromine

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0026457
UMLS CUI [1,2]
C0205156
UMLS CUI [2]
C0016855
UMLS CUI [3]
C0031392
UMLS CUI [4]
C0033223
UMLS CUI [5]
C0036579
UMLS CUI [6]
C0040778
Volver a la parte superior de la página

Similar models

Eligibility Breast Cancer NCT00873366

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
Tamoxifen | Prophylactic treatment Breast Carcinoma TNM Breast tumor staging | Prophylactic treatment Invasive carcinoma of breast TNM Breast tumor staging | Therapeutic procedure Breast Carcinoma TNM Breast tumor staging | Therapeutic procedure Invasive carcinoma of breast TNM Breast tumor staging
Item
eligible to receive tamoxifen for 6 months for either the prevention or treatment of non-invasive or invasive, stage i-iii breast cancer
boolean
C0039286 (UMLS CUI [1])
C0199176 (UMLS CUI [2,1])
C0678222 (UMLS CUI [2,2])
C0474926 (UMLS CUI [2,3])
C0199176 (UMLS CUI [3,1])
C0853879 (UMLS CUI [3,2])
C0474926 (UMLS CUI [3,3])
C0087111 (UMLS CUI [4,1])
C0678222 (UMLS CUI [4,2])
C0474926 (UMLS CUI [4,3])
C0087111 (UMLS CUI [5,1])
C0853879 (UMLS CUI [5,2])
C0474926 (UMLS CUI [5,3])
CYP2D6 gene Known
Item
cyp2d6 genotype known
boolean
C1332830 (UMLS CUI [1,1])
C0205309 (UMLS CUI [1,2])
CYP2D6 gene Poor metabolizer | cytochrome p450 2D6 genotype | Breath Test
Item
patients determined to be cyp2d6 poor metabolizers (by determination of a genotype test by their mayo physician prior to study registration) are eligible to proceed with the initial breath test only
boolean
C1332830 (UMLS CUI [1,1])
C3845231 (UMLS CUI [1,2])
C2164095 (UMLS CUI [2])
C0006153 (UMLS CUI [3])
Hormone Receptor Status Unspecified
Item
hormone receptor status not specified
boolean
C0019929 (UMLS CUI [1,1])
C0449438 (UMLS CUI [1,2])
C0205370 (UMLS CUI [1,3])
Client Characteristics
Item
patient characteristics:
boolean
C0815172 (UMLS CUI [1])
Menopausal Status Unspecified
Item
menopausal status not specified
boolean
C3829127 (UMLS CUI [1,1])
C0205370 (UMLS CUI [1,2])
ECOG performance status
Item
ecog performance status 0-2
boolean
C1520224 (UMLS CUI [1])
Life Expectancy
Item
life expectancy > 6 months
boolean
C0023671 (UMLS CUI [1])
Exclusion Liver Dysfunction Grade | Aspartate aminotransferase measurement | Alkaline phosphatase measurement | Serum total bilirubin measurement
Item
no known impaired hepatic activity defined as ≥ grade 3 ast, alkaline phosphatase, or total bilirubin
boolean
C2828389 (UMLS CUI [1,1])
C0086565 (UMLS CUI [1,2])
C0441800 (UMLS CUI [1,3])
C0201899 (UMLS CUI [2])
C0201850 (UMLS CUI [3])
C1278039 (UMLS CUI [4])
Exclusion Criteria | Lung disease Associated with Hypercapnia | Asthma | Respiration Disorders
Item
no pulmonary disease (e.g., asthma or other respiratory disease) associated with hypercapnia
boolean
C0680251 (UMLS CUI [1])
C0024115 (UMLS CUI [2,1])
C0332281 (UMLS CUI [2,2])
C0020440 (UMLS CUI [2,3])
C0004096 (UMLS CUI [3])
C0035204 (UMLS CUI [4])
Exclusion Criteria | Metabolic Diseases Uncontrolled | Gastroparesis due to diabetes mellitus | Congestive heart failure Uncontrolled | Gastrointestinal Diseases Uncontrolled | Gastroesophageal reflux disease
Item
no uncontrolled metabolic disease (e.g., diabetes in the presence of gastroparesis, uncontrolled congestive heart failure, or uncontrolled gastrointestinal disorders [e.g., gerd])
boolean
C0680251 (UMLS CUI [1])
C0025517 (UMLS CUI [2,1])
C0205318 (UMLS CUI [2,2])
C0267176 (UMLS CUI [3])
C0018802 (UMLS CUI [4,1])
C0205318 (UMLS CUI [4,2])
C0017178 (UMLS CUI [5,1])
C0205318 (UMLS CUI [5,2])
C0017168 (UMLS CUI [6])
Exclusion Adverse reactions Dextromethorphan
Item
no prior adverse reaction to dextromethorphan
boolean
C2828389 (UMLS CUI [1,1])
C0559546 (UMLS CUI [1,2])
C0011816 (UMLS CUI [1,3])
Exclusion Criteria | Chronic liver disease | Hepatitis B, Chronic | Hepatitis C, Chronic | Chronic alcoholic liver disease | Liver Cirrhosis chronic | Chronic fibrosis
Item
no history of chronic liver disease (e.g., hepatitis b or hepatitis c, alcoholic liver disease, cirrhosis, or fibrotic disease)
boolean
C0680251 (UMLS CUI [1])
C0341439 (UMLS CUI [2])
C0524909 (UMLS CUI [3])
C0524910 (UMLS CUI [4])
C4076349 (UMLS CUI [5])
C0023890 (UMLS CUI [6,1])
C0205191 (UMLS CUI [6,2])
C0334133 (UMLS CUI [7])
Fasting Overnight Able | Fasting Overnight Willing
Item
able and willing to fast overnight prior to the study session
boolean
C0015663 (UMLS CUI [1,1])
C0439583 (UMLS CUI [1,2])
C0085732 (UMLS CUI [1,3])
C0015663 (UMLS CUI [2,1])
C0439583 (UMLS CUI [2,2])
C0600109 (UMLS CUI [2,3])
Follow-up Willing
Item
willing to return to mayo clinic for follow-up
boolean
C3274571 (UMLS CUI [1,1])
C0600109 (UMLS CUI [1,2])
Biospecimen Provide Willing
Item
willing to provide biologic specimens
boolean
C2347026 (UMLS CUI [1,1])
C1999230 (UMLS CUI [1,2])
C0600109 (UMLS CUI [1,3])
Therapeutic procedure
Item
prior concurrent therapy:
boolean
C0087111 (UMLS CUI [1])
Pharmaceutical Preparations Previous Slowing Gastric Emptying | Pharmaceutical Preparations Previous Slowing Gastrointestinal Motility | Alcohol | Analgesics, Opioid | Anticholinergic Agents | Antihistamines | Loperamide
Item
more than 24 hours since prior medications known to slow gastric emptying or gastrointestinal motility (e.g., alcohol, opioid analgesics, anticholinergics [e.g., antihistamines], and loperamide)
boolean
C0013227 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C0439834 (UMLS CUI [1,3])
C0017127 (UMLS CUI [1,4])
C0013227 (UMLS CUI [2,1])
C0205156 (UMLS CUI [2,2])
C0439834 (UMLS CUI [2,3])
C0017184 (UMLS CUI [2,4])
C0001975 (UMLS CUI [3])
C0002772 (UMLS CUI [4])
C0242896 (UMLS CUI [5])
C0019590 (UMLS CUI [6])
C0023992 (UMLS CUI [7])
C0162373 (UMLS CUI [8])
CYP2D6 Inhibitors Previous | Selective Serotonin Reuptake Inhibitors Previous | Paroxetine | Paxil | Fluoxetine | Prozac
Item
more than 4 weeks since prior and no concurrent cyp2d6 inhibitors or concurrent serotonin-reuptake inhibitors known to be potent cyp2d6 inhibitors (e.g.,paroxetine [paxil®] and fluoxetine [prozac®]
boolean
C3850058 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C0360105 (UMLS CUI [2,1])
C0205156 (UMLS CUI [2,2])
C0070122 (UMLS CUI [3])
C0376414 (UMLS CUI [4])
C0016365 (UMLS CUI [5])
C0162373 (UMLS CUI [6])
CYP2D6 Inhibitors Mild Patient need for | CYP2D6 Inhibitors Moderate Patient need for
Item
if mild to moderate inhibitors of cyp2d6 are medically necessary, patients may go back on after the 8-week time point
boolean
C3850058 (UMLS CUI [1,1])
C2945599 (UMLS CUI [1,2])
C0686904 (UMLS CUI [1,3])
C3850058 (UMLS CUI [2,1])
C0205081 (UMLS CUI [2,2])
C0686904 (UMLS CUI [2,3])
Monoamine Oxidase Inhibitors Previous | Furazolidone | Phenelzine | Procarbazine | Selegiline | Tranylcypromine
Item
more than 4 weeks since prior and no concurrent monoamine-oxidase inhibitors (e.g., furazolidone, phenelzine, procarbazine, selegiline, and tranylcypromine)
boolean
C0026457 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C0016855 (UMLS CUI [2])
C0031392 (UMLS CUI [3])
C0033223 (UMLS CUI [4])
C0036579 (UMLS CUI [5])
C0040778 (UMLS CUI [6])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial